TY - JOUR
T1 - Perspectives and Advances in the Understanding of Tuberculosis
AU - Kinsella, Rachel L.
AU - Zhu, Dennis X.
AU - Harrison, Gregory A.
AU - Mayer Bridwell, Anne E.
AU - Prusa, Jerome
AU - Chavez, Sthefany M.
AU - Stallings, Christina L.
N1 - Funding Information:
The authors thank members of the Stallings lab for their careful reading of drafts and suggestions. C.L.S. is supported by the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) grants AI132653, AI132697, AI142784, AI111696, and AI134847 and by a Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease award. R.L.K. is supported by a Potts Memorial Foundation postdoctoral fellowship. G.A.H. is supported by the National Science Foundation Graduate Research Fellowship Program award DGE-1745038 and by the NIH/National Institute of General Medical Sciences grant GM007067. D.X.Z. is supported by the NIH/NIAID grant A1007172.
Publisher Copyright:
© 2021 Annual Reviews Inc.. All rights reserved.
PY - 2021/1/24
Y1 - 2021/1/24
N2 - Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), remains a leading cause of death due to infection in humans. To more effectively combat this pandemic, many aspects of TB control must be developed, including better point of care diagnostics, shorter and safer drug regimens, and a protective vaccine. To address all these areas of need, better understanding of the pathogen, host responses, and clinical manifestations of the disease is required. Recently, the application of cutting-edge technologies to the study of Mtb pathogenesis has resulted in significant advances in basic biology, vaccine development, and antibiotic discovery. This leaves us in an exciting era of Mtb research in which our understanding of this deadly infection is improving at a faster rate than ever, and renews hope in our fight to end TB. In this review, we reflect on what is known regarding Mtb pathogenesis, highlighting recent breakthroughs that will provide leverage for the next leaps forward in the field.
AB - Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), remains a leading cause of death due to infection in humans. To more effectively combat this pandemic, many aspects of TB control must be developed, including better point of care diagnostics, shorter and safer drug regimens, and a protective vaccine. To address all these areas of need, better understanding of the pathogen, host responses, and clinical manifestations of the disease is required. Recently, the application of cutting-edge technologies to the study of Mtb pathogenesis has resulted in significant advances in basic biology, vaccine development, and antibiotic discovery. This leaves us in an exciting era of Mtb research in which our understanding of this deadly infection is improving at a faster rate than ever, and renews hope in our fight to end TB. In this review, we reflect on what is known regarding Mtb pathogenesis, highlighting recent breakthroughs that will provide leverage for the next leaps forward in the field.
KW - Host response
KW - Infection
KW - Mycobacteria
KW - Pathogenesis
KW - Virulence
UR - http://www.scopus.com/inward/record.url?scp=85100259908&partnerID=8YFLogxK
U2 - 10.1146/annurev-pathol-042120-032916
DO - 10.1146/annurev-pathol-042120-032916
M3 - Review article
C2 - 33497258
AN - SCOPUS:85100259908
SN - 1553-4006
VL - 16
SP - 377
EP - 408
JO - Annual Review of Pathology: Mechanisms of Disease
JF - Annual Review of Pathology: Mechanisms of Disease
ER -